Purdue announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets. Hysingla ER was approved in November 2014 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in patients for whom alternative treatment options are inadequate.

Hysingla ER, a Schedule II narcotic, is the first hydrocodone entity recognized as having abuse-deterrent properties that are expected to deter misuse and abuse via chewing, snorting, and injection. It incorporates the Company’s proprietary RESISTEC platform for extended-release solid oral dosage formulations. It uses unique polymer and processing that confers tablet hardness and viscosity when dissolved in aqueous solutions.

RELATED: How is Hysingla ER Different from Other Opioids?

Hydrocodone binds to and activates opioid receptors in the brain and spinal cord, which are coupled to G-protein complexes and modulate synaptic transmission through adenylate cyclase. The pharmacological effects of hydrocodone including analgesia, euphoria, respiratory depression and physiological dependence are believed to be primarily mediated via mu-opioid receptors.

Hysingla ER is available in 20mg, 30mg, 40mg, 60mg, 80mg, 100mg, and 120mg strength tablets.

For more information call (888) 726-7535 or visit HysinglaER.com.